报价延迟最少15分钟:2025/11/19 08:24 EST
盘前时段
|
||||
|
1.45 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.38
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.63/-0.21
|
|
企业价值
25.45M
|
| 资产负债 |
|
每股账面净值
0.43
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/11/19 08:24 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in theapplication of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing. |
